Safety and Efficacy of Ixmyelocel-T
Authors:
- Timothy D. HenryTHTimothy D. Henry
- Jay H. TraverseJTJay H. Traverse
- Baron L. HammonBHBaron L. Hammon
- Cara A. EastCECara A. East
- Brian BrucknerBBBrian Bruckner
- Ann E. RemmersARAnn E. Remmers
- David ReckerDRDavid Recker
- David A. BullDBDavid A. Bull
- Amit N. PatelAPAmit N. Patel
Open Access
- 26 September 2014
- journal article
- research article
- Published by Wolters Kluwer Health in Circulation Research
- Vol. 115 (8) , 730-737
Abstract
Rationale: Ixmyelocel-T is associated with a wide range of biological activities relevant to tissue repair and regeneration. Objective: To evaluate the safety and efficacy of ixmyelocel-T in 2 prospective randomized phase 2A Trials administered via minithoracotomy or intramyocardial catheter injections in patients with dilated cardiomyopathy (DCM) stratified by ischemic or nonischemic status. Methods and Results: In IMPACT-DCM, patients were randomized to either ixmyelocel-T or standard-of-care control in a 3:1 ratio (n=39); ixmyelocel-T was administered intramyocardially via minithoracotomy. In Catheter-DCM, patients were randomized to either ixmyelocel-T or standard of care control in a 2:1 ratio (n=22); ixmyelocel-T was administered intramyocardially using the NOGA Myostar catheter. Only patients randomized to ixmyelocel-T underwent bone marrow aspiration and injections. In the 2 studies, a total of 61 patients were randomized, and 59 were treated or received standard of care. Fewer ischemic patients treated with ixmyelocel-T experienced a major adverse cardiovascular event during follow-up when compared with control patients. A similar benefit was not seen in the nonischemic patients. Heart failure exacerbation was the most common major adverse cardiovascular event. Ixmyelocel-T treatment was associated with improved New York Heart Association class, 6-minute walk distance, and Minnesota Living with Heart Failure Questionnaire scores in the ischemic population relative to control; a similar trend was not observed in the nonischemic population. Conclusions: Intramyocardial injection with ixmyelocel-T reduces major adverse cardiovascular event and improves symptoms in patients with ischemic DCM but not in patients with nonischemic DCM.Keywords
This publication has 25 references indexed in Scilit:
- Bone Marrow Stem Cell Treatment for Ischemic Heart Disease in Patients with No Option of Revascularization: A Systematic Review and Meta-AnalysisPLOS ONE, 2013
- Forecasting the Impact of Heart Failure in the United StatesCirculation: Heart Failure, 2013
- The Temporal and Spatial Distribution of Macrophage Subpopulations During ArteriogenesisCurrent Vascular Pharmacology, 2013
- Cellular Therapy With Ixmyelocel-T to Treat Critical Limb Ischemia: The Randomized, Double-blind, Placebo-controlled RESTORE-CLI TrialMolecular Therapy, 2012
- Effect of Transendocardial Delivery of Autologous Bone Marrow Mononuclear Cells on Functional Capacity, Left Ventricular Function, and Perfusion in Chronic Heart FailureJAMA, 2012
- RETRACTED: Cardiac stem cells in patients with ischaemic cardiomyopathy (SCIPIO): initial results of a randomised phase 1 trialThe Lancet, 2011
- The composition of the mesenchymal stromal cell compartment in human bone marrow changes during development and agingHaematologica, 2011
- Intramyocardial, Autologous CD34+ Cell Therapy for Refractory AnginaCirculation Research, 2011
- Age-related changes in human bone marrow-derived mesenchymal stem cells: Consequences for cell therapiesMechanisms of Ageing and Development, 2008
- The chemokine system in arteriogenesis and hind limb ischemiaJournal of Vascular Surgery, 2007